Performance and clinical utility of supervised machine-learning approaches in detecting familial

Ralph K Akyea1, Nadeem Qureshi1, Joe Kai1

  • 1Primary Care Stratified Medicine, Division of Primary Care, University of Nottingham, Nottingham, UK.

NPJ Digital Medicine
|November 4, 2020
PubMed

Insights

Machine learning models significantly improve the detection of familial hypercholesterolaemia (FH), an inherited cholesterol disorder. Ensemble learning offers the best balance of accuracy and clinical utility for identifying FH cases in primary care.

Area of Science:

  • Cardiovascular Medicine
  • Medical Informatics
  • Genetics

Background:

  • Familial hypercholesterolaemia (FH) is a common genetic disorder causing elevated LDL cholesterol, leading to premature heart disease.
  • Most FH cases remain undiagnosed, missing opportunities for early intervention and prevention.
  • Machine learning (ML) shows promise for FH detection in electronic health records, but clinical utility needs further assessment.

Purpose of the Study:

  • To evaluate the performance and clinical utility of various ML algorithms for enhancing FH detection in a large primary care population.
  • To compare the predictive accuracy and case-finding workload of different ML models in identifying FH.

Main Methods:

  • A retrospective cohort study analyzed 4,027,775 UK primary care records (1999-2019).
  • Five ML algorithms (logistic regression, random forest, gradient boosting, neural networks, ensemble learning) were assessed for FH detection.
  • Performance metrics included AUC, calibration slope, likelihood ratios, and expected case-review workload.

Main Results:

  • Four ML approaches (excluding logistic regression) demonstrated high predictive accuracy (AUC > 0.89).
  • Ensemble learning achieved the highest positive likelihood ratio (45.5) and a low case-review workload (0.73%).
  • ML models identified novel predictive features, such as raised triglycerides, which can decrease FH likelihood.

Conclusions:

  • ML models offer high accuracy for FH detection, presenting opportunities to increase diagnosis rates.
  • Different ML models vary significantly in their clinical case-finding workload and efficiency.
  • Ensemble learning appears most promising for efficient and accurate FH case identification in primary care settings.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
281
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
212